A Case of Anaplastic Thyroid Cancer with Long-term Survival

被引：0

作者：

Koussis, Haralabos ^{[1
]}

Maruzzo, Marco ^{[1
]}

Scola, Annamaria ^{[4
,5
]}

Ide, Eric Casal ^{[2
]}

Fassina, Ambrogio

Marioni, Gino ^{[6
]}

Lora, Ornella ^{[3
]}

Corti, Luigi ^{[3
]}

Karachontziti, Paraskevi ^{[7
]}

Jirillo, Antonio ^{[1
]}

机构：

[1] Ist Oncol Veneto IRCCS, Dept Med Oncol, I-35128 Padua, Italy

[2] Ist Oncol Veneto IRCCS, Dept Surg Oncol, I-35128 Padua, Italy

[3] Ist Oncol Veneto IRCCS, Dept Radiat Oncol, I-35128 Padua, Italy

[4] Azienda ULSS 12, Dept Med Oncol, Venice, Italy

[5] Univ Padua, Sch Med, Dept Pathol, Padua, Italy

[6] Univ Padua, Sch Med, Dept Otolaryngol, Padua, Italy

[7] Iaso Matern Hosp, Dept Radiat Oncol, Athens, Greece

来源：

ANTICANCER RESEARCH | 2010年 / 30卷 / 04期

关键词：

Case report; anaplastic thyroid carcinoma; multimodal treatment; chemotherapy; long-term survival; PROGNOSTIC-FACTORS; IN-VITRO; CARCINOMA; PACLITAXEL; CHEMOTHERAPY; BIOLOGY; GROWTH; CELLS; BRAF;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Anaplastic thyroid carcinoma (ATC) (less than 10% of all thyroid cancer) is a high-grade neoplasm, characterized by an aggressive clinical course and refractoriness to currently available local and systemic modalities of treatment. It is considered the most aggressive solid tumour, there is no adequate therapy for this disease and few patients with ATC live more than 1 year following diagnosis. We report herein an unusual case of ATC in a 59-year-old woman. She presented to our Institute in December 2004. She received many kinds of chemotherapeutical and multimodal treatment; we obtained a long period of localized disease (about two years) and an excellent response to therapy. She is still alive 58 months from diagnosis.

引用

页码：1273 / 1278

页数：6

共 30 条

[1] Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo [J].

Ain, KB ;

Tofiq, S ;

Taylor, KD .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (10) :3650-3653

[2] Anaplastic thyroid carcinoma: Behavior, biology, and therapeutic approaches [J].

Ain, KB .

THYROID, 1998, 8 (08) :715-726

[3] Treatment of anaplastic thyroid carcinoma with paclitaxel: Phase 2 trial using ninety-six-hour infusion [J].

Ain, KB ;

Egorin, MJ ;

DeSimone, PA .

THYROID, 2000, 10 (07) :587-594

[4] Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches [J].

Are, C ;

Shaha, AR .

ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (04) :453-464

[5]

Batori M, 2007, EUR REV MED PHARMACO, V11, P69

[6] Docetaxel in the management of patients with head and neck squamous cell carcinoma [J].

Bernier, Jacques ;

Vrieling, Conny .

EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) :1023-1032

[7] Anaplastic thyroid carcinoma: clinical outcome of 30 consecutive patients referred to a single institution in the past 5 years [J].

Brignardello, Enrico ;

Gallo, Marco ;

Baldi, Ileana ;

Palestini, Nicola ;

Piovesan, Alessandro ;

Grossi, Emidio ;

Ciccone, Giovannino ;

Boccuzzi, Giuseppe .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2007, 156 (04) :425-430

[8]

Chaplin DJ, 1999, ANTICANCER RES, V19, P189

[9] Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy [J].

De Crevoisier, R ;

Baudin, E ;

Bachelot, A ;

Leboulleux, S ;

Travagli, JP ;

Caillou, B ;

Schlumberger, M .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04) :1137-1143

[10] Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): Efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis [J].

Escudier, B. J. ;

Ravaud, A. ;

Negrier, S. ;

Szczylik, C. ;

Bellmunt Molins, J. ;

Bracarda, S. ;

Pisa, P. ;

Gaudreault, J. ;

Bajetta, E. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)

← 1 2 3 →